BioMarin Pharmaceutical Inc.
NASDAQ:BMRNBiotechnology
-$0.10 today
- Market cap
- $11.90B
- Beta
- 0.24
- P/E (TTM)
- 39.4
- EPS (TTM)
- $1.40
Volume 3.07M
Average 2.04M
BMRN Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
BioMarin Pharmaceutical Inc.NASDAQ: BMRN
Net Receivables · Q3 FY2026 · quarter ended Sep 2026
Net receivables rises 136101.6% from a year ago
Net receivables stood at $1.08T at the end of Q3 FY2026, up 136101.6% from a year earlier and up 101342.7% from the prior quarter. Over 3 fiscal years it compounded at +25.3% a year.
Context
- Net receivables amounted to 9.3% of total assets at the end of Q3 FY2026, down 1.1 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +136101.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 908.21M USD
- Year-over-year change
- +37.5%
- 4-year CAGR
- +24.9%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 908.21M | +37.5% |
| FY2024 | 2024-12-31 | 660.54M | +4.2% |
| FY2023 | 2023-12-31 | 633.7M | +37.4% |
| FY2022 | 2022-12-31 | 461.32M | +23.5% |
| FY2021 | 2021-12-31 | 373.4M | — |
Net Receivables vs competitors
How BMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +136101.6% is the highest of 11, against a peer median of +45.3%.
- Net receivables amounts to 9.3% of total assets for BMRN, versus a peer median of 10.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.08T USD | +136101.6% | +25.3% | 9.3% | |
| Sep 2026 | $2.31B USD | +18.7% | +12.5% | 7.1% | |
| Jun 2026 | $912.74M USD | +60.9% | +48.4% | 16.4% | |
| Jun 2026 | $254.48M USD | +231.1% | +101.4% | 20.9% | |
| Sep 2026 | €242.52M EUR | +64.7% | +136.5% | 10.0% | |
| Jun 2026 | $239.04M USD | +21.9% | +5.3% | 7.4% | |
| Jun 2026 | $215.33M USD | +291.3% | +68.0% | 10.2% | |
| Mar 2026 | $121M USD | +22.4% | +57.8% | 9.3% | |
| Sep 2026 | $107.53M USD | +29.6% | +68.9% | 12.7% | |
| Sep 2026 | $88.34M USD | +253.4% | +37.2% | 3.0% | |
| Mar 2026 | $60.03M USD | +26.4% | +29.2% | 12.3% | |
| Peer median (excluding BMRN) | — | +45.3% | +53.1% | 10.1% | |
Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 587.28M | 724.53M | 755.13M | 942.84M | 1.31B |
| Short-term Investments | 426.6M | 567.01M | 318.68M | 194.86M | 248.93M |
| Net Receivables | 373.4M | 461.32M | 633.7M | 660.54M | 908.21M |
| Inventory | 776.67M | 894.08M | 1.11B | 1.23B | 1.3B |
| Other Current Assets | 110.44M | 104.52M | 141.39M | 201.53M | 185.78M |
| Total Current Assets | 2.27B | 2.75B | 2.96B | 3.23B | 3.95B |
| Property, Plant & Equipment (Net) | 1.04B | 1.07B | 1.07B | 1.04B | 952.51M |
| Goodwill | 196.2M | 196.2M | 196.2M | 196.2M | 196.2M |
| Intangible Assets | 388.65M | 338.57M | 294.7M | 255.28M | 213.84M |
| Long-term Investments | 507.79M | 333.84M | 611.14M | 521.24M | 498.21M |
| Tax Assets | 1.45B | 1.51B | 1.55B | 1.49B | 1.51B |
| Other Non-current Assets | 152.12M | 176.24M | 171.54M | 251.39M | 277.05M |
| Total Non-current Assets | 3.73B | 3.62B | 3.89B | 3.76B | 3.64B |
| Total Assets | 6B | 6.38B | 6.84B | 6.99B | 7.59B |
| Account Payables | 199.68M | 231.24M | 315.51M | 235.4M | 312.77M |
| Short-term Debt | 0 | 0 | 493.88M | 23.07M | 8.69M |
| Tax Payables | 1.21M | 16.21M | 2.65M | 12.57M | 0 |
| Deferred Revenue | 6.96M | 711K | 4.62M | 1.37M | 0 |
| Other Current Liabilities | 258.94M | 236.1M | 234.92M | 132.07M | 210.72M |
| Total Current Liabilities | 546.5M | 588.88M | 1.18B | 606.99M | 759.03M |
| Long-term Debt | 1.08B | 1.08B | 593.1M | 595.14M | 597.18M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 113.53M | 100.02M | 119.94M | 97.57M | 113.8M |
| Total Non-current Liabilities | 1.19B | 1.18B | 713.03M | 723.96M | 747.99M |
| Total Liabilities | 1.74B | 1.77B | 1.89B | 1.33B | 1.51B |
| Common Stock | 184K | 186K | 189K | 191K | 192K |
| Retained Earnings | (930.76M) | (789.2M) | (621.55M) | (194.7M) | 154.21M |
| Accumulated OCI | 14.43M | (3.87M) | (28.79M) | 61.65M | (13.47M) |
| Other Stockholders Equity | (9.69M) | (8.86M) | (9.86M) | (11.23M) | (10.51M) |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 4.27B | 4.6B | 4.95B | 5.66B | 6.09B |
| Total Debt | 1.09B | 1.09B | 1.1B | 649.47M | 642.87M |
| Net Debt | 502.27M | 368.86M | 340.62M | (293.38M) | (668.81M) |
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
Intrinsic Alpha fair value
Locked
Current Price
$61.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.